We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Gentian Diagnostics Exhibits Assays for Wide Range of Clinical Chemistry Platforms at EUROMEDLAB

By LabMedica International staff writers
Posted on 11 Apr 2022

Gentian Diagnostics (Moss, Norway) exhibited its range of assays for highly relevant biomarkers for a wide range of clinical chemistry platforms at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EUROMEDLAB) in Munich, Germany. More...

Gentian demonstrated its Calprotectin Immunoassay (GCAL) assay, which is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation. Calprotectin in plasma and serum is a sensitive and early biomarker in detection of inflammation and inflammatory response in infections. Calprotectin has been reported as diagnostic marker in the discrimination between bacterial and viral infection, in assessment of severe infections and sepsis and in the prediction for development of severe infections. Interestingly, calprotectin has also been reported a risk marker in severe COVID-19, which in contrast to other viral infection induces a hyperinflammation response and pathways mimic bacterial sepsis. Gentian’s GCAL is an open channel assay, meaning it can be added to all clinical chemistry analyzers.

Gentian also promoted its turbidimetric Cystatin C Immunoassay which is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. Cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function1 for patients of all ages. The Cystatin C Immunoassay has documented high inter-instrument accuracy on a wide range of clinical chemistry analyzers. Gentian also promoted its new turbidimetric SARS-CoV-2 Total Antibody Immunoassay which is a quantitative antibody test that captures the full immune response detecting antibodies targeting the S1-subunit with high sensitivity and specificity. It will be calibrated against the international WHO international standard. Since the Gentian assay is platform agnostic, it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost. The test follows a standard testing protocol utilizing existing logistic structure, from the routine blood test at the GP office to the clinical chemistry platforms with an assay time of only 10 minutes.

Related Links:
Gentian Diagnostics 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette Calibration System
Artel PCS®
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.